Beam Therapeutics Announces Portfolio Progress and Reports Third Quarter 2022 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/6/2026
Go back to Beam Therapeutics Announces Portfolio Progress and Reports Third Quarter 2022 Financial Results
November 7, 2022 10:51 AM EST
RBC Capital analyst Luca Issi lowered the price target on Beam Therapeutics Inc (NASDAQ: BEAM) to $60.00 (from $76.00) while maintaining a Sector Perform rating.
The analyst comments "BEAM is prioritizing the lead HbF-boosting SCD program over the next-gen Makassar. We caught up... More
November 7, 2022 9:32 AM EST
Stifel analyst Benjamin Burnett lowered the price target on Beam Therapeutics Inc (NASDAQ: BEAM) to $103.00 (from $120.00) while maintaining a Buy rating.
The analyst comments "We are reiterating our Buy rating on BEAM following 3Q22 updates. Main pushbacks from bears have been on (potentially... More
November 7, 2022 6:32 AM EST
Beam, Inc. (NASDAQ: BEAM) reported Q3 EPS of ($1.56), $0.28 worse than the analyst estimate of ($1.28). Revenue for the quarter came in at $15.8 million versus the consensus estimate of $7.15 million.
Ended Third Quarter 2022 with $1.1 Billion in Cash, Cash Equivalents and Marketable Securities.
For earnings... More
